Scientific Library
3 Reasons to use fresh TLR9 agonists
As part of the innate immune response, Toll-like receptor 9 recognizes unmethylated CpG nucleotide sequences, which are very common in viruses and prokaryotes and more rare in vetebrates. Scientists routinely
Cas9 mRNA optimized for genome editing
CRISPR/Cas9 is relatively simple to
Two top ways to success with knock-out
In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out
Simple and effective CRISPR CAS9 gene editing for primary cells
Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications
A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA
Enhance Your Therapeutic mRNA Research Projects with Modified NTPs
How Modified NTPs are Revolutionising mRNA Vaccine Technology
In recent years, the spotlight on mRNA (messenger RNA) technology has intensified, largely due to its pivotal role
Optimising mRNA for Therapeutics: The Synergy of CleanCap Technology and Minimal UTRs
mRNA and UTRs: Unlocking New Frontiers in Therapeutic Innovation
Over the past five years, there has been an explosive surge in scientific interest surrounding messenger RNA (mRNA),
Revolutionising mRNA Production: When Simplicity Meets Efficiency
mRNA-Based Therapeutics: Pioneering the Future of Medicine
Over the past few years, mRNA-based therapeutics have emerged as a promising approach to treat various diseases, including
Unlocking the Next Frontier in Immuno-Oncology: Powering T and NK Cell Therapies with Nanotein’s Innovative Platforms
Powering T and NK Cell Therapies with Nanotein’s Innovative Platforms
In the ever-evolving field of immuno-oncology, the race to develop the most effective cell-based therapies has never been
Self-Amplifying RNA Tools for High-Impact Research: TriLink’s New saRNA Reporters Now Available
Explore TriLink’s new self-amplifying RNA (saRNA) constructs—eGFP and FLuc—now available at Tebubio. Designed for high expression, reduced immunogenicity, and enhanced stability.